Lung Cancer
Lung cancer and mesothelioma risks in a prospective cohort of workers with asbestos-related lung or pleural diseases
American Journal of Industrial Medicine 2022 June 1 [Link] Dirk Taeger, Katharina Wichert, Martin Lehnert, Swaantje Casjens, Beate Pesch, Daniel G Weber, Thomas Brüning, Georg Johnen, Thomas Behrens Abstract Background: Asbestos causes mesothelioma and lung cancer. In the European Union, asbestos was banned in 2005, but it is still in use in many other countries.…
Read MoreHeadspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
Frontiers in Oncology 2022 May 6 [Link] Eline Janssens, Zoë Mol, Lore Vandermeersch, Sabrina Lagniau, Karim Y Vermaelen, Jan P van Meerbeeck, Christophe Walgraeve, Elly Marcq, Kevin Lamote Abstract Introduction: Malignant pleural mesothelioma (MPM) is a lethal cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs) in breath proved to be…
Read MoreEffects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma
Scientific Reports 2022 May 23 [Link] Misa Ichikawa, Naomi Muramatsu, Wataru Matsunaga, Takahiro Ishikawa, Tomoyuki Okuda, Hirokazu Okamoto, Akinobu Gotoh Abstract Gene therapy using vectors has attracted attention in recent years for the treatment of cancers caused by gene mutations. Besides, new treatments are imperative for lung cancer, including non-small cell lung cancer (NSCLC) and…
Read MoreDiagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels
Medicine 2022 January 7 [Link] Takeshi Saraya, Kosuke Ohkuma, Masachika Fujiwara, Haruyuki Ishii Abstract Malignant mesothelioma (MM) is difficult to diagnose because of the lack of parenchymal opacities, often revealing minimal or absent pleural thickening. Furthermore, pleural effusion has diverse differential diagnoses, including malignancies, infections, as well as collagen vascular and other benign diseases. In…
Read MoreHighly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies
Biomedical Chromatography 2021 November 5 [Link] Eleonora W J van Ewijk-Beneken Kolmer, Marga J A Teulen, Rene J Boosman, Nikki de Rouw, Jacobus A Burgers, Rob Ter Heine Abstract Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may…
Read MoreThe Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma
International Journal of Molecular Sciences 2021 July 10 [Link] Li Yuan, Boshu Sun, Liangliang Xu, Limin Chen, Wenbin Ou Abstract SET domain bifurcated 1 (SETDB1) is a histone H3 lysine 9 (H3K9) methyltransferase that exerts important effects on epigenetic gene regulation. SETDB1 complexes (SETDB1-KRAB-KAP1, SETDB1-DNMT3A, SETDB1-PML, SETDB1-ATF7IP-MBD1) play crucial roles in the processes of histone…
Read MoreAn EBC/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls
Frontiers in Oncology 2021 June 15 [Link] Alice Faversani, Chiara Favero, Laura Dioni, Angela Cecilia Pesatori, Valentina Bollati, Matteo Montoli, Valeria Musso, Andrea Terrasi, Nicola Fusco, Mario Nosotti, Valentina Vaira, Alessandro Palleschi Abstract Background: Despite significant improvement in screening programs for cancers of the respiratory district, especially in at-risk subjects, early disease detection is still…
Read MoreControversies in the role of radiotherapy in pleural mesothelioma
Translational Lung Cancer Research 2021 April [Link] Gerard G Hanna, Thomas John, David L Ball Abstract Malignant pleural mesothelioma is an uncommon thoracic cancer with a relatively poor outcome, which has only seen modest improvements when compared to non-small cell lung cancer. The mainstays of treatment have been surgery and systemic therapy, with radiation reserved…
Read MoreUtility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma
The American Journal of Surgical Pathology 2021 March 29 [Link] Julia R Naso, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract The separation of malignant mesothelioma from non-small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled homolog 2 (DAB2) have recently been proposed as sensitive/specific markers of…
Read MoreHigh sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
ERJ Open Research 2021 March 22 [Link] Lars Hagmeyer, Stephan Schäfer, Marianne Engels, Anja Pietzke-Calcagnile, Marcel Treml, Simon-Dominik Herkenrath, Matthias Heldwein, Khosro Hekmat, Sandhya Matthes, Andreas Scheel, Jürgen Wolf, Reinhard Büttner, Winfried Randerath Abstract Background: Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) immune checkpoint inhibitors have been approved for monotherapy…
Read More
Skip to content